CPG 7909 Injection in Non-Small Cell Lung Cancer

Status Completed

Clinical Trial Summary

Eligible patients will be randomized in a ratio of 2:1 to receive either chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection or chemotherapy alone. Protocol therapy will be administered until disease progression or intolerable toxicity. CpG 7909 Injection will be administered subcutaneously, on Weeks 2 and 3 of each three-week cycle (days 8 and 15) and chemotherapy will be administered on Week 1 (Day 1). Patients will undergo complete disease evaluation at the end of every other treatment cycle until disease progression.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00070629
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 2
Start date	May 2003
Completion date	July 2007

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04486833` - Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib	Phase 1/Phase 2
Terminated	`NCT00321308` - Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer	Phase 2
Completed	`NCT00190840` - A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer	Phase 2
Terminated	`NCT01441128` - -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer	Phase 1
Recruiting	`NCT05358249` - Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	Phase 1/Phase 2
Terminated	`NCT02961283` - Study of ASN003 in Subjects With Advanced Solid Tumors	Phase 1
Recruiting	`NCT00973310` - Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer	Phase 2
Completed	`NCT00385996` - Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer	Phase 2
Terminated	`NCT02775006` - Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma	Phase 3
Completed	`NCT03232593` - A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
Terminated	`NCT02590003` - Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer	Phase 2
Terminated	`NCT01514864` - Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation	Phase 2
Completed	`NCT02079636` - A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)	Phase 1
Completed	`NCT01079520` - Endobronchial Ultrasound- Transbronchial Needle Aspiration (EBUS-TBNA) Versus Mediastinoscopy for Mediastinal Lymph Node Staging of Non-small Cell Lung Cancer (NSCLC)	N/A
Terminated	`NCT01115803` - A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors	Phase 1
Completed	`NCT00861627` - Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation	Phase 2
Completed	`NCT00923884` - Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer
Recruiting	`NCT04389632` - A Study of SGN-B6A in Advanced Solid Tumors	Phase 1
Terminated	`NCT03603652` - NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung	N/A
Not yet recruiting	`NCT01131429` - A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations	Phase 2